AU Patent

AU2013231109B2 — Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid

Assigned to Vertex Pharmaceuticals Inc · Expires 2015-10-29 · 11y expired

What this patent protects

Abstract The present invention relates to a substantially crystalline and free solid state form of 3-(6-(1 (2,2-difluoro benzo [d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylPyridin-2 yl)benzoic acid (Form I) of following formula: (I), pharmaceutical compositions thereof,…

USPTO Abstract

Abstract The present invention relates to a substantially crystalline and free solid state form of 3-(6-(1 (2,2-difluoro benzo [d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylPyridin-2 yl)benzoic acid (Form I) of following formula: (I), pharmaceutical compositions thereof, and methods of treatment therewith. e o -Oo

Drugs covered by this patent

Patent Metadata

Patent number
AU2013231109B2
Jurisdiction
AU
Classification
—
Expires
2015-10-29
Drug substance claim
No
Drug product claim
No
Assignee
Vertex Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.